98%
921
2 minutes
20
Angiocentric glioma (AG) is a supratentorial diffuse low-grade glioma characterized by the MYB::QKI fusion gene, showing angiocentric growth of monomorphous spindle cells with astrocytic and ependymal immunophenotypes. We describe a rare case of MYB::QKI fusion-positive diffuse cerebellar glioma in a 54-year-old male. The patient initially presented with a T2/FLAIR hyperintense lesion in the left cerebellar hemisphere and slowly progressive neurological symptoms. Histopathological evaluation revealed a diffuse glioma characterized by spindle-shaped and small epithelioid cells with perivascular infiltration. Immunohistochemistry showed positivity for glial fibrillary acidic protein and only occasionally positive for Olig2. No dot- or ring-like epithelial membrane antigen immunoreactivity was observed. In this case, the proliferative activity was higher than that in typical AG cases, as manifested by multiple mitoses (four mitoses/slide) and a Ki-67 labeling index of 5%. The tumor cells were negative for IDH1 p.R132H and H3 p.K28M mutation-specific antibodies. Fluorescence in situ hybridization showed a MYB break-apart signal, and reverse transcription-polymerase chain reaction analysis confirmed an in-frame MYB (6q23.3, exon 11, NM_001161659.2)::QKI (6q26, exon 5, NM_006775.3) fusion. IDH1 p.R132, IDH2 p.R172, H3-3A p.K28, H3C2 p.K28, and BRAF p.V600 were all wild type. DNA methylome profiling did not match any of the established methylation classes, including the four subtypes of diffuse glioma, MYB- or MYBL1-altered. Considering the results of DNA methylome profiling, the question remains as to whether this case represents a subset of AG (diffuse glioma, MYB/MYBL1-altered) or a distinct subtype. Although the morphological findings and the presence of fusion indicated that the tumor was a cerebellar AG, the DNA methylome profile did not match that of AG. An accumulation of more cases is needed to determine the precise nature of the tumor, which may lead to an expansion of the tumor concept.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/neup.13016 | DOI Listing |
Eur J Nucl Med Mol Imaging
September 2025
Department of Nuclear Medicine, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
Purpose: Amino acid PET with [F]-fluoroethylthyrosine ([F]FET-PET) is frequently utilized in gliomas. Most studies on prognostication based on amino acid PET comprise mixed cohorts of brain tumors with low- and high-grade features. The objective of this study was to assess the potential prognostic value of [F]FET-PET-based markers in the group of grade 2 adult-type diffuse gliomas, as defined by the WHO CNS 2021 classification.
View Article and Find Full Text PDFActa Neuropathol
September 2025
Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
J Feline Med Surg
September 2025
Department for Small Animals, Veterinary Faculty, Leipzig University, Leipzig, Germany.
ObjectivesThe objective of this study was to evaluate the occurrence of voltage-gated potassium channel (VGKC) antibodies and the pattern of MRI changes in cats with complex partial seizures with orofacial involvement (CPSOFI), as well as to investigate whether there are factors influencing survival that could be used as prognostic markers in those cats.MethodsCats with CPSOFI were identified retrospectively. The following data were retrieved from the hospital database: signalment, age at first seizure and presentation, the presence of antibodies against VGKC (leucine-rich glioma inactivating factor 1 (LGI1), contactin-associated protein 2 (CASPR2)) and cerebrospinal fluid (CSF) analysis findings.
View Article and Find Full Text PDFBrain Imaging Behav
September 2025
Department of Critical Care Medicine, Beijing Tiantan Hospital, Capital Medical University, South 4th Ring West Road 119, Fengtai District, Beijing, 100070, China.
To explore the effect of brain cognitive compensation on the pathogenesis of postoperative delirium (POD) in the frontal glioma patients. Eighty-four adult patients with unilateral frontal glioma who underwent elective craniotomy and 37 healthy controls were recruited. Primary outcomes were POD during postoperative 1-7 days, as assessed by Confusion Assessment Method.
View Article and Find Full Text PDFPharmacoecon Open
September 2025
Acaster Lloyd Consulting Ltd, Lacon House, 84 Theobalds Rd, London, WC1X 8NL, UK.
Background: Isocitrate dehydrogenase-mutant (mIDH) gliomas are malignant central nervous system tumours. After initial resection, patients with mIDH gliomas with favourable prognosis may live without receiving oncologic treatment for years, but ultimately patients will experience recurrence and require radio- and/or chemotherapy (RT/CT). Cost-utility analyses (CUA) can explore the value of treatments that delay recurrence and initiation of RT/CT.
View Article and Find Full Text PDF